Cdk5 Inhibitors
Items 31 to 39 of 39 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cdk/Crk Inhibitor | 784211-09-2 | sc-203872 | 1 mg | $290.00 | ||
Cdk/Crk Inhibitor functions by selectively disrupting the activity of Cdk5, a critical kinase involved in neuronal signaling. This compound exhibits unique binding affinity through hydrophobic interactions and hydrogen bonding, which alters the conformational dynamics of the enzyme. Its ability to modulate allosteric sites can lead to significant changes in substrate recognition and phosphorylation patterns, thereby influencing downstream signaling pathways. Additionally, its stability in various pH environments enhances its potential for diverse biochemical applications. | ||||||
(R)-2-((9-Isopropyl-6-((3-(pyridin-2-yl)phenyl)-amino)-9H-purin-2-yl)amino)butan-1-ol | 1056016-06-8 | sc-296248 sc-296248A | 50 mg 100 mg | $800.00 $1400.00 | ||
The compound (R)-2-((9-Isopropyl-6-((3-(pyridin-2-yl)phenyl)-amino)-9H-purin-2-yl)amino)butan-1-ol exhibits a remarkable capacity to modulate Cdk5 activity through intricate molecular interactions. Its unique structural features facilitate specific electrostatic and hydrophobic contacts, promoting selective inhibition. This compound's kinetic profile reveals a nuanced influence on enzyme turnover rates, potentially reshaping cellular signaling cascades and regulatory mechanisms. | ||||||
CR8, (S)-Isomer | 1084893-56-0 | sc-311307 | 5 mg | $201.00 | ||
CR8, the (S)-isomer, demonstrates a distinctive ability to interact with Cdk5, characterized by its selective binding affinity and unique conformational dynamics. This compound engages in specific hydrogen bonding and hydrophobic interactions, which enhance its inhibitory potency. Its reaction kinetics suggest a non-competitive inhibition mechanism, allowing for fine-tuning of enzymatic activity. The compound's structural attributes contribute to its role in modulating cellular pathways, influencing downstream signaling events. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib exhibits a remarkable capacity to modulate Cdk5 activity through its intricate molecular interactions. It forms stable complexes with the enzyme, leveraging both van der Waals forces and electrostatic interactions to achieve high specificity. The compound's kinetic profile indicates a reversible inhibition mechanism, allowing for dynamic regulation of Cdk5-mediated pathways. Its unique structural features facilitate selective targeting, influencing cellular processes with precision. | ||||||
TAK 165 | 366017-09-6 | sc-361372 sc-361372A | 10 mg 50 mg | $139.00 $781.00 | ||
TAK 165 demonstrates a distinctive ability to interact with Cdk5, characterized by its selective binding affinity. The compound engages in hydrogen bonding and hydrophobic interactions, enhancing its specificity for the enzyme. Its kinetic behavior reveals a competitive inhibition pattern, allowing for nuanced modulation of Cdk5 activity. The structural architecture of TAK 165 promotes unique conformational changes in the enzyme, influencing downstream signaling pathways with targeted efficacy. | ||||||
MeBIO | 667463-95-8 | sc-357370 | 10 mg | $163.00 | 1 | |
MeBIO exhibits a remarkable capacity to modulate Cdk5 activity through its unique binding dynamics. The compound forms stable complexes with the enzyme, leveraging both ionic and van der Waals interactions to enhance selectivity. Its reaction kinetics indicate a non-competitive inhibition mechanism, allowing for effective regulation of Cdk5 without competing directly with substrate binding. Additionally, MeBIO's structural features facilitate allosteric modulation, impacting enzyme conformation and function. | ||||||
Cdk1 Inhibitor | 220749-41-7 | sc-202529 | 5 mg | $124.00 | 3 | |
Cdk1 Inhibitor demonstrates a distinctive ability to selectively target Cdk5 by engaging in specific hydrogen bonding and hydrophobic interactions. This compound alters the enzyme's active site conformation, leading to a unique inhibition profile characterized by mixed-type kinetics. Its structural attributes promote enhanced binding affinity, allowing for nuanced modulation of Cdk5 activity. Furthermore, the inhibitor's dynamic behavior in solution contributes to its efficacy in disrupting key signaling pathways. | ||||||
BML-259 | 267654-00-2 | sc-202505 | 5 mg | $127.00 | 1 | |
BML-259 exhibits a remarkable selectivity for Cdk5 through its unique molecular architecture, which facilitates specific electrostatic interactions and steric hindrance. This compound effectively stabilizes an inactive conformation of Cdk5, resulting in a distinctive inhibition mechanism that showcases competitive and non-competitive characteristics. Its solubility properties enhance its interaction dynamics, allowing for precise modulation of enzymatic activity and influencing downstream cellular processes. | ||||||
Aloisine, RP106 | 496864-15-4 | sc-202452 sc-202452A | 1 mg 5 mg | $31.00 $139.00 | ||
Aloisine, RP106, demonstrates a unique affinity for Cdk5, characterized by its ability to form specific hydrogen bonds and hydrophobic interactions that modulate the enzyme's active site. This compound alters the conformational landscape of Cdk5, promoting a distinct allosteric inhibition pathway. Its kinetic profile reveals a nuanced interaction with substrate binding, leading to altered reaction rates and influencing the overall enzymatic cascade within cellular signaling networks. | ||||||